Oral cladribine phase 3 results show relapse reductions, lower total cost for patients with RRMS
New analyses from the phase 3 CLARITY (Cladribine Tablets Treating MS Orally) study reveal improvements in disease-free activity and the annualized relapse rate and a reduction in the use of healthcare resources in cladribine recipients compared with placebo in patients with relapsing-remitting multiple sclerosis (RRMS).
Key Points
New analyses from the phase 3 CLARITY (Cladribine Tablets Treating MS Orally) study reveal improvements in disease-free activity and the annualized relapse rate (ARR) and a reduction in the use of healthcare resources in cladribine recipients compared with placebo in patients with relapsing-remitting multiple sclerosis (RRMS).
The updates were presented during several presentations delivered at the 62nd annual meeting of the American Academy of Neurology, Toronto.
CLARITY was a 96-week, double-blind study in which 1,320 patients with RRMS were randomly assigned to 1 of 2 doses of cladribine or placebo orally. Patients randomly assigned to cladribine were treated with either 2 (3.5 mg/kg total dose) or 4 (5.25 mg/kg total dose) courses during the first year, with each course consisting of once-daily administration for 4 or 5 days (8 to 20 days of treatment total during the first year). During the second year, all patients randomly assigned to cladribine were treated with 2 courses (total treatment of 8 to 10 days during year 2).
Among the new findings presented:
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
